Darcy Lewis

Articles

Ibrutinib-containing Combination Induced High Rate of Bone Marrow MRD Negativity, 100% ORR in IGHV-Mutated CLL

July 12th 2017

Patients with IGHV-mutated chronic lymphocytic leukemia had high rates of minimal residual disease-negative status in bone marrow following first-line treatment with a combination of ibrutinib (Imbruvica), fludarabine, cyclophosphamide, and obinutuzumab.

Maintenance Olaparib Shows Promise in Platinum-Sensitive Serous Ovarian Cancer

June 16th 2017

The PARP inhibitor olaparib demonstrated clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer in a recent study.

Study Further Characterizes Niraparib PFS Benefit in Ovarian Cancer

June 9th 2017

Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline BRCA mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

Experts Provide Tips on Setting Up a Successful Community-Based Clinical Trials Program

November 8th 2016

Clinical research in private practice is thriving and the future is bright.

LUGPA Will Create Bundled Payment Models for Prostate Care

November 8th 2016

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models

November 7th 2016

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Systemic Immunotherapy Use Expanding Rapidly in Bladder Cancer

November 6th 2016

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

Novel Therapies Offer Hope for BCG-Unresponsive Bladder Cancer

November 5th 2016

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.

Bladder Cancer Biomarkers Aid in Diagnosis, Monitoring

November 5th 2016

When it comes to the burgeoning arena of biomarkers in bladder cancer, the value proposition is compelling, although the utility and costs need to be better defined, according to Badrinath Konety, MD, MBA.

Atezolizumab and Cobimetinib Regimen Shows Activity in CRC

June 15th 2016

In patients with advanced colorectal cancer, the combination regimen of cobimetinib (Cotellic) and atezolizumab (Tecentriq) was found to demonstrate clinical activity as well as have a good safety profile.

Survival Benefit Observed With Olaparib in Ovarian Cancer

June 9th 2016

In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib (Lynparza) was found to significantly increase overall survival when given as maintenance therapy.

Genetics Should Dictate Treatment for WaldenstrÃ¶m's Macroglobulinemia

November 3rd 2015

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with WaldenstrÃ¶m's macroglobulinemia.

Novel Agents Improve MCL Care, Tumor Profiling Key to Further Advances

October 21st 2015

Novel agents have transformed the treatment of mantle cell lymphoma and tumor profiling is poised to further enhance these benefits.

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL

October 20th 2015

John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib and idelalisib in chronic lymphocytic leukemia, as well as unanswered questions and challenges concerning these novel agents.

Fosbretabulin/Bevacizumab Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

March 31st 2015

Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.

Bevacizumab Regimen Shows Survival Trend in Phase III Ovarian Cancer Trial

March 30th 2015

Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Studies Illuminate Olaparib's Continued Role in Ovarian Cancer

March 30th 2015

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib in the treatment of women with ovarian cancer, according to Ursula A. Matulonis, MD.

Expert Predicts the Future of Immune Therapies for Lung Cancer

November 1st 2014

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC

November 1st 2014

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.